Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone Acetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | PGR | P06401 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | IL5 | P05113 | 1/20 | 0.75 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.75 |
| ▸ | AR | P10275 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | MMP9 | P14780 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
| ▸ | THPO | P40225 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexbudesonide SCHEMBL4260550 | 0.91 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1ALMNAPGR | |
| Dexbudesonide SCHEMBL18695366 | 0.91 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1ALMNAPGR | |
| Desonide SCHEMBL2115498 | 0.88 | CYP3A4 (0.75) | CYP3A4NR3C1HIF1ALMNAPGR | |
| Desonide SCHEMBL11778722 | 0.87 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1ALMNAPGR | |
| SCHEMBL10337827 | 0.87 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1ALMNAPGR | |
| SCHEMBL7134775 | 0.87 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1ALMNAPGR | |
| SCHEMBL7741442 | 0.87 | CYP3A4 (0.73) | CYP3A4NR3C1HIF1ALMNAPGR | |
| Flunisolide SCHEMBL2393174 | 0.87 | NR3C1 (0.79) | CYP3A4NR3C1HIF1ALMNAPGR | |
| Budesonide SCHEMBL1130417 | 0.87 | NR3C1 (1.00) | CYP3A4NR3C1HIF1ALMNAPGR | |
| Budesonide SCHEMBL13695912 | 0.87 | NR3C1 (1.00) | CYP3A4NR3C1HIF1ALMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117062609-A | Methods for treating or preventing acute respiratory distress syndrome | CSL创新私人有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4262872-A1 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL Innovation Pty Ltd (AU) | 2023-10-25 | — | — | EP | disclosed |
| US-20230272087-A1 | METHOD OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL LIMITED AND CSL INNOVATION PTY LTD (AU) | 2023-08-31 | — | — | US | disclosed |
| EP-4161576-A1 | METHOD OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL Innovation Pty Ltd (AU) | 2023-04-12 | — | — | EP | disclosed |
| CN-115768475-A | Methods of treating or preventing acute respiratory distress syndrome | CSL创新私人有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022133519-A1 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL Innovation Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-20190160150-A1 | ACTH FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2019-05-30 | — | — | US | disclosed |
| US-10232018-B2 | ACTH for treatment of acute respiratory distress syndrome | MALLINCKRODT ARD IP LIMITED (IE) | 2019-03-19 | — | — | US | disclosed |
| US-10117974-B2 | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions | ARROW INTERNATIONAL, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10016532-B2 | Non-fouling, anti-microbial, anti-thrombogenic graft compositions | ARROW INTERNATIONAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2968475-A2 | ACTH FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | Questcor Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9096703-B2 | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions | SEMPRUS BIOSCIENCES CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150056411-A1 | NON-FOULING, ANTI-MICROBIAL, ANTI-THROMBOGENIC GRAFT COMPOSITIONS | TELEFLEX LIFE SCIENCES LIMITED (MT) | 2015-02-26 | — | — | US | disclosed |
| US-20150045515-A1 | NON-FOULING, ANTI-MICROBIAL, ANTI-THROMBOGENIC GRAFT-FROM COMPOSITIONS | TELEFLEX LIFE SCIENCES LIMITED (MT) | 2015-02-12 | — | — | US | disclosed |
| US-20140322226-A1 | ACTH FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | QUESTCOR PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014153221-A2 | ACTH FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | QUESTCOR PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2579904-A2 | NON-FOULING, ANTI-MICROBIAL, ANTI-THROMBOGENIC GRAFT COMPOSITIONS | Semprus Biosciences Corp. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2579908-A2 | NON-FOULING, ANTI-MICROBIAL, ANTI-THROMBOGENIC GRAFT-FROM COMPOSITIONS | Semprus Biosciences Corporation (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20110305898-A1 | NON-FOULING, ANTI-MICROBIAL, ANTI-THROMBOGENIC GRAFT COMPOSITIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2011-12-15 | — | — | US | disclosed |